Iran breaks Denmark's factor VII monopoly

TEHRAN, Jun. 24 (MNA) – An Iranian company inaugurated its AryoSeven production line, breaking the Danish monopoly over the medicine.

AryoSeven which has so far been monopolistically produced by a Danish company, is now manufactured by an Iranian science-based company thanks to the research and endeavor of Iranian pharmacologists and the support provided by the Deputy of Science and Technology Department of the Presidential Office of Islamic Republic.

Made out of Baby Hamster Kidney fibroblasts, AryoSeven is a biosimilar recombinant form of human factor VII and is commonly prescribed for people with hemophilia (with Factor VIII or IX deficiency) who have developed inhibitors against replacement coagulation factor.

Factor VII is one of the proteins that cause blood to clot in the coagulation cascade. It is an enzyme of the serine protease class.

We are to start our export to Russia and Turkey as all the licenses have been obtained and filing for the EU approval is underway, the MD of the company told the reporters.

The Danish copy of the drug is priced 1000$ a package while the Iranian one is sold one-third of that fee to Iran’s Drug and Food Organization.  

 

News Code 108138

Tags

Your Comment

You are replying to: .
  • 1 + 6 =

    Comments

    • Published Comments: 2
    • Pending Comments: 0
    • Rejected Comments: 0
    • also good for you 11:06 - 2015/06/24
      0 0
      does the man think about the "baby hamsters" who give their lives family and friends to help "humans" ? :)
    • tiptoe 12:26 - 2015/06/24
      0 0
      Welldone